Treatment of metastatic colorectal cancer by means of specific monoclonal antibodies conjugated with iodine-131: a phase II study
| Autor: | P. Morigi, V. Tison, Nb. Riva, M. Marangolo, A. Spinelli, R. Tassini, G. Moscatelli, D. Tirindelli, P. Riva, G. Franceschi, G. Vecchietti, L. Armaroli |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class Colorectal cancer medicine.medical_treatment Phases of clinical research Adenocarcinoma Monoclonal antibody Gastroenterology Iodine Radioisotopes Antigens Neoplasm Internal medicine medicine Humans Aged Chemotherapy Rectal Neoplasms business.industry Antibodies Monoclonal Radiotherapy Dosage General Medicine Middle Aged medicine.disease Surgery Concomitant Colonic Neoplasms Toxicity Drug Evaluation Female business Adjuvant Progressive disease |
| Zdroj: | International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology. 18:109-119 |
| ISSN: | 0883-2897 |
| Popis: | Eighteen consecutive patients with advanced and/or metastatic colorectal carcinoma have been treated with intraperitoneal administration of radiolabelled (iodine-131) monoclonal antibodies raised against different antigens associated to these kinds of tumours: anti-CEA FO23C5, anti-CEA BW494/32, anti-TAG B72.3, AUA1. The doses of isotope ranged between 21 and 150 mCi (777–5550 MBq) which delivered a radiation dose to the target tumour from 768 to 4628 cGy. Thirteen patients were previously treated with conventional regimens which consisted of chemotherapy (5-fluoracil with or without other anti-neoplastic drugs) both in adjuvant or palliative setting. Three patients are considered non-evaluable owing to concomitant chemotherapy in 2 and lack of objective parameters in 1. Out of 15 evaluable patients 2 achieved complete remission and 2 partial remission with a response rate of 26.6%. Three stable and 8 with progressive disease have also been registered. The toxicity was negligible consisting of hematologic WHO grade 1 in 7 patients, grade 2 in 1 patient and grade 3 in 1 patient, as well as hepatic WHO grade 1 in 8 and grade 2 in 2 patients. The authors conclude that this innovative way of treatment for advanced colorectal carcinoma seems to offer promising therapy; from these data, therefore, a new trial is justified employing radiolabelled MoAbs in well selected patients with metastatic or locally advanced colorectal carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|